Form 4: United Therapeutics Director Christopher Causey Executes Stock Option and Sells Shares

Director Christopher Causey exercised stock options and sold shares of United Therapeutics Corp on May 3, 2024.

Summary

• On May 3, 2024, Christopher Causey, a director of United Therapeutics Corporation, exercised stock options to acquire 2,240 shares of common stock at a price of $112.14 per share.
• Simultaneously, Causey sold 2,240 shares of common stock at a price of $259.9085 per share.
• Following these transactions, Causey directly owns 4,185 shares of United Therapeutics common stock.
• Causey also holds 7,000 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates